RVL Pharmaceuticals plc
RVL Pharmaceuticals plc (RVLP): 3 pipeline candidates · ~5 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.3 months
D/E 4.23 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for RVL Pharmaceuticals plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$19.2M
Quarterly Burn
$12.1M
Runway
5.3 mo
Revenue
$8.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| arbaclofen | Phase 3 |
| arbaclofen er | Phase 3 |
| upneeq | Approved |
Frequently asked questions
How many drug candidates are in RVL Pharmaceuticals plc's pipeline?
RVL Pharmaceuticals plc (RVLP) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is RVL Pharmaceuticals plc's lead drug candidate?
RVL Pharmaceuticals plc's most advanced tracked candidate is arbaclofen (Phase 3) for Spasticity in Patients With Multiple Sclerosis (Study OS440.
What is RVL Pharmaceuticals plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, RVL Pharmaceuticals plc has approximately 5.3 months of cash runway.
Get the full picture on RVL Pharmaceuticals plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.